Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 457

1.

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.

Ann Intern Med. 2000 Apr 4;132(7):566-77. Erratum in: Ann Intern Med. 2005 Nov 15;143(10):764-5.

PMID:
10744594
2.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

3.

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N.

Cancer. 2002 Jul 15;95(2):361-76. Review.

4.

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Bayoumi AM, Brown AD, Garber AM.

J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9.

PMID:
11058616
5.

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.

Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD.

Urology. 1997 Jan;49(1):71-8.

PMID:
9000189
6.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481
7.

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.

Moreau JP, Delavault P, Blumberg J.

Clin Ther. 2006 Oct;28(10):1485-508. Review. Erratum in: Clin Ther. 2006 Nov;28(11):1970.

PMID:
17157109
8.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
9.

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.

Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, Bennett CL.

Urology. 2001 Apr;57(4):727-32.

PMID:
11306391
11.

Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.

Moul JW, Fowler JE Jr.

Urology. 2003 Dec 22;62(6 Suppl 1):20-8.

PMID:
14706505
12.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

13.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
14.

Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.

Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G.

J Steroid Biochem. 1986 Nov;25(5B):877-83.

PMID:
3100871
15.

Is the flare phenomenon clinically significant?

Bubley GJ.

Urology. 2001 Aug;58(2 Suppl 1):5-9. Review.

PMID:
11502435
17.

Hormonal therapy: historical perspective to future directions.

Mcleod DG.

Urology. 2003 Feb;61(2 Suppl 1):3-7. Review.

PMID:
12667881
18.
19.

Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

BJU Int. 2015 Jul;116(1):30-6. doi: 10.1111/bju.13026. Epub 2015 Mar 23. Review.

20.

Maximal androgen blockade for advanced prostate cancer.

Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T.

Cochrane Database Syst Rev. 2000;(2):CD001526. Review.

PMID:
10796804

Supplemental Content

Support Center